C12P 21 - Preparation of peptides or proteins

Patents for C12P 21 - Preparation of peptides or proteins (112,499)
11/2006
11/15/2006	EP1222281B1 Immunoligically significant herpes simplex virus antigens
11/15/2006	EP1206493B1 Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
11/15/2006	EP1064372B1 Compounds and methods for therapy and diagnosis of lung cancer
11/15/2006	EP1051502B1 Highly efficient controlled expression of exogenous genes in e. coli
11/15/2006	EP1008351B1 Carcinostatic agents
11/15/2006	EP0758381B2 Biologically active eph family ligands
11/15/2006	CN1863921A Methods for expression and purification of immunotoxins
11/15/2006	CN1863920A Conjugation of peptides
11/15/2006	CN1863818A Anti-VEGF antibodies
11/15/2006	CN1863815A Polypeptides having brain disposition activity and utilization of the same
11/15/2006	CN1863556A Compositions and methods for treating coagulation related disorders
11/15/2006	CN1861801A Collagen wet-retaining face mask and preparation process thereof
11/15/2006	CN1861796A Process of preparing duck alpha-interferon expressing gene in bacillus coli and insect cell
11/15/2006	CN1861790A Preparation process of human recombined parathyroid hormone 1 84
11/15/2006	CN1284860C Single clone antibody of antimutagen hepatitis B virus surface antigen and preparation method thereof
11/15/2006	CN1284859C Membrane virus host range mutations and their uses as vaccine substrates
11/15/2006	CN1284850C Method for the recombinant production of polypeptides
11/15/2006	CN1284797C Method for constructing, expressing and purifying human recombination factor and application
11/14/2006	US7135612 Identification of the gene causing the mouse scurfy phenotype and its human ortholog
11/14/2006	US7135605 Metal binding proteins and associated methods
11/14/2006	US7135555 Mammalian TNF-α convertases
11/14/2006	US7135338 Methods for overexpression of high molecular weight form of mannose binding lectin (MBL) and a specific formulation for active treatment for systemic infection with microorganism
11/14/2006	US7135334 Stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more
11/14/2006	US7135326 UDP-glucosyltransferases
11/14/2006	US7135322 In mammalian cells deficient in furin proteolytic enzyme
11/14/2006	US7135321 Truncated glycogen synthase kinase 3 crystallizable polypeptide; drug screening for Alzheimer's Disease treatments, antidiabetic and antiinflammatory agents
11/14/2006	US7135318 Modified reductase and its gene
11/14/2006	US7135316 Escherichia coli having accession No. PTA 1579 and its use to produce polyhydroxybutyrate
11/14/2006	US7135309 Processes for the bioconversion of a fermentable carbon source to 1,3-propanediol by a single microorganism
11/14/2006	US7135303 Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
11/14/2006	US7135297 Isolated biopolymer marker peptide; using mass spectrometry to determine markers predictive of insulin resistance
11/14/2006	US7135185 Conserved motif of hepatitis C virus E2/NS1 region
11/14/2006	US7135182 Administration of substrates for transglutaminases or antibodies against such substrates; identification, prevention or treatment of microbial infection of mammalian hosts such as immunocompromised or immunosuppressed humans
11/14/2006	US7135181 Method for down-regulation of amyloid
11/14/2006	US7135177 Immunoliposomes that optimize internalization into target cells
11/14/2006	US7135176 VMP-like sequences of pathogenic Borrelia
11/14/2006	US7135175 Compositions and methods for eliciting an immune response to gram-negative bacterial infections
11/14/2006	US7135174 Antibodies directed to PDGFD and uses thereof
11/14/2006	US7135171 Endothelial precursor cells for enhancing and restoring vascular function
11/14/2006	CA2239224C Topiramate immunoassay, as well as analogs and antibodies
11/12/2006	CA2606334A1 Methods of using phhla2 to co-stimulate t-cells
11/09/2006	WO2006119285A1 Combination therapy in the treatment of cancer
11/09/2006	WO2006118350A1 Anti-platelet membrane glycoprotein vi monoclonal antibody
11/09/2006	WO2006118289A1 Method for identification of compound having antidepressant effect
11/09/2006	WO2006117910A1 Monoclonal antibody against platelet membrane glycoprotein vi
11/09/2006	WO2006082058A3 Cell-free translation system for the production of (chemically) modified proteins
11/09/2006	WO2006009928A3 Galnts as modifiers of the igfr pathway and methods of use
11/09/2006	WO2006009903A3 High throughput cancer pharmaceutical screening using drosophila
11/09/2006	WO2005116236A3 Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
11/09/2006	WO1998035042A8 Activity dependent neurotrophic factor iii (adnf iii)
11/09/2006	US20060253928 Optimizing glycan processing in plants
11/09/2006	US20060253924 Nucleotide sequences involved in disease resistance
11/09/2006	US20060253914 Ha4,a new osteoblast-and chondrocyte-specific small secreted peptide, compositions and methods of use
11/09/2006	US20060253913 Production of hSA-linked butyrylcholinesterases in transgenic mammals
11/09/2006	US20060253912 Nucleotide and amino acid sequences of oocyte factors for altering ovarian follicular growth in vivo or in vitro
11/09/2006	US20060253911 nucleotide sequences characterized that part of its sequence is replaced with a sequence capable of undergoing specific DNA recombination by Cre recombinase; used in RNA interference induction, for analyzing gene function
11/09/2006	US20060252922 Compositions, splice variants and methods relating to colon specific genes and proteins
11/09/2006	US20060252921 Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens
11/09/2006	US20060252919 Vegf variant that lacks vegfr-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis
11/09/2006	US20060252915 Inhibit the growth of microorganisms in environments with physiological salt concentrations and at the same time have as low as possible a hemolytic activity
11/09/2006	US20060252695 Analysis and separation of platelet-derived growth factor proteins
11/09/2006	US20060252690 Factor VII or VIIa - Like Molecules
11/09/2006	US20060252689 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders
11/09/2006	US20060252680 Genes whose expression is increased in response to stimulation by corticotropin-releasing hormone
11/09/2006	US20060252678 Lowering circulating free fatty acid levels, reducing body mass, maintaining weight loss, and treating obesity-related diseases and disorders
11/09/2006	US20060252677 Postsynaptic proteins
11/09/2006	US20060252676 Analgesic antitumor peptide from scorpion and method of producing it
11/09/2006	US20060252157 Larynx carcinoma-associated protein larcap-1
11/09/2006	US20060252130 Method for linking molecular substances
11/09/2006	US20060252129 Human coagulation Factor VII variants
11/09/2006	US20060252128 FVII OR FVIIa GLA DOMAIN VARIANTS
11/09/2006	US20060252127 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders
11/09/2006	US20060252126 Polypeptides having phospholipase B activity and nucleic acids encoding same
11/09/2006	US20060252125 ICE/CED-3 like protease designated FMH-1
11/09/2006	US20060252124 Methods and compositions for generating human monoclonal antibodies
11/09/2006	US20060252123 Glucose dehydrogenase beta subunit and DNA encoding the same
11/09/2006	US20060252122 A tumor necrosis factor related ligand
11/09/2006	US20060252121 Epilepsy mutations
11/09/2006	US20060252120 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
11/09/2006	US20060252119 FBL2-specific agents as modulators of Flaviviridae RNA replication
11/09/2006	US20060252118 Operably linking to a T7 promoter, a truncated TAP (thermolabile Antarctic phosphatase) gene fused to a sequence for expressing a hydrophilic oligopeptide; transforming a host cell; overexpressing TAP
11/09/2006	US20060252117 Fusion proteins; immunogens; acute liver disease; alcholic liver failure
11/09/2006	US20060252116 Icam-4 binding sites
11/09/2006	US20060252115 Synthesis and use of anti-reverse mRNA cap analogues
11/09/2006	US20060252106 Monoclonal antibodies and methods for their use in the detection of cervical disease
11/09/2006	US20060252100 Can be used for the treatment of diabetes or for delaying the onset of diabetes
11/09/2006	US20060252098 Isolated DNA encoding cullin regulators ROC1 and ROC2, isolated proteins encoded by the same, and methods utilizing the same
11/09/2006	US20060252096 Single chain antibody with cleavable linker
11/09/2006	US20060252080 Feline hemoplasma isolate
11/09/2006	US20060252051 Method for producing diverse libraries of encoded polymers
11/09/2006	US20060252037 Expression vector comprising antisense nuclelotide sequence which decrease exxpression from kinase suppressor of RAS (KRAS) for use in the treatment and prevention of cell proliferative disorders
11/09/2006	US20060252034 Novel protein containing ring finger domaine r1p4
11/09/2006	US20060252028 Method of assaying interaction between proteins
11/09/2006	US20060251763 Phospholipase variants
11/09/2006	US20060251699 Anti-angiogenic peptides from the N-terminus of endostatin
11/09/2006	US20060251671 Haemophilus influenza outer membrane protein and use thereof in vaccination
11/09/2006	US20060251668 Tumor-specific recognition molecules
11/09/2006	US20060251666 Cancer antigens and utilization thereof
11/09/2006	US20060251665 Vaccines
11/09/2006	US20060251660 Antibodies to human IL-1beta

1 ... 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 ... 1125